BCM
TRML

Bridgeway Capital Management’s Tourmaline Bio TRML Stock Holding History

Bridgeway Capital Management’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,267
Closed -$310K – 1253
2024
Q4 		$310K Sell
15,267
-2,000
-12% -$50.4K 0.01% 915
2024
Q3 		$444K Hold
17,267
– – 0.01% 892
2024
Q2 		$222K Hold
17,267
– – 0.01% 1040
2024
Q1 		$395K Sell
17,267
-14,850
-46% -$524K 0.01% 984
2023
Q4 		$841K Buy
32,117
+1,999
+7% +$40K 0.02% 799
2023
Q3 		$846K Buy
30,118
+15,188
+102% +$445K 0.02% 752
2023
Q2 		$454K Buy
14,930
+2,140
+17% +$54.6K 0.01% 929
2023
Q1 		$240K Sell
12,790
-3,650
-22% -$60.2K 0.01% 1069
2022
Q4 		$168K Buy
16,440
+15,290
+1,330% +$246K ﹤0.01% 1129
2022
Q3 		$30K Buy
+1,150
New +$41.9K ﹤0.01% 1374

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Bridgeway Capital Management's TRML Position: Q1 2025 in Review

Bridgeway Capital Management sold out of Tourmaline Bio (TRML) in Q1 2025, closing a stake of 15,267 shares — an estimated $310K sold.

Bridgeway Capital Management first reported a position in TRML in Q3 2022 and held it in 10 quarters. The position peaked at $846K in Q3 2023. 107 funds tracked by Wall St. Rank hold TRML as of Q1 2025.

  • Bridgeway Capital Management reported no remaining Tourmaline Bio position as of Q1 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 15,267 Tourmaline Bio shares in Q1 2025, an estimated $310K.
  • Bridgeway Capital Management first reported a position in Tourmaline Bio in Q3 2022 and held it in 10 quarters.
  • Bridgeway Capital Management's Tourmaline Bio position peaked at $846K in Q3 2023.
  • 107 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2025.

Based on Bridgeway Capital Management's 13F filing for Q1 2025, filed 15 May 2025.